OncoMatch/Clinical Trials/NCT05238922
Study of INCB123667 in Subjects With Advanced Solid Tumors
Is NCT05238922 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments for solid tumors.
Treatment: INCB0123667 · Palbociclib · Bevacizumab · Olaparib · Paclitaxel · Ribociclib · Fulvestrant — This is an open-label, dose-escalation and dose-expansion study to determine the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy of INCB123667 when administered as monotherapy and in combination with anticancer therapies in participants with selected advanced or metastatic solid tumors. This study will consist of 2 parts. In Part 1, INCB123667 will be administered as monotherapy and in Part 2, INCB123667 will be administered in combination with anticancer therapies of interest. Each part will comprise a dose escalation portion (Parts 1a and 2a, respectively) and a dose-expansion portion (Parts 1b and 2b, respectively).
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Disease stage
Required: Stage IV
Metastatic disease required
advanced or metastatic solid tumors; Measurable lesions by CT or MRI based on RECIST v1.1 criteria
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard treatment
Disease progression on prior standard treatment, intolerance to or ineligibility for standard treatment, or no available treatment to improve the disease outcome
Cannot have received: CDK2 inhibitor
Prior treatment with any CDK2 inhibitor
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope Medical Center · Duarte, California
- City of Hope-Lennar Foundation Cancer Center · Irvine, California
- Valkyrie Clinical Trials · Los Angeles, California
- Rocky Mountain Cancer Centers-Sky Ridge · Lone Tree, Colorado
- Yale Cancer Center · New Haven, Connecticut
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify